Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NNC6022-0001
- Development stage
- Phase 1
- Lead developer
- Novo Nordisk
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NNC6022-0001 is an investigational oral small molecule inhibitor of NLRP3 (NACHT, LRR and PYD domains-containing protein 3), a key component of the inflammasome pathway involved in inflammation. Originally developed by Ventus Therapeutics as VENT-01, it was licensed to Novo Nordisk in September 2022 for global development and commercialization. The drug is being evaluated for its potential to treat a range of cardiometabolic diseases, including metabolic dysfunction-associated steatohepatitis (MASH), chronic kidney disease, obesity, and other related conditions. A Phase 1 clinical trial began in 2024 to assess safety, pharmacokinetics, and pharmacodynamics in healthy volunteers.
- Other names
- VENT-01VENT01VENT 01NNC6022-0001NNC-6022-0001NNC 6022-0001
02
Targets
NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)
Beyond the preview
Go deeper on NNC6022-0001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NNC6022-0001.